- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04348565
Diabetes Care Programme for Type 2 Diabetes Mellitus in Primary Care Setting
An Evaluation of the Effect of a Diabetes Care Programme for People With Type 2 Diabetes Mellitus in Primary Care Setting: A Randomized Controlled Trial
Uncontrolled metabolic parameters and co-morbidity risk factors cause Diabetes Mellitus as the leading cause of a multitude of micro-/macro-vascular complications. According to the International Guidelines and Recommendations, people with Type 2 Diabetes Mellitus (T2DM) should attend diabetes educational programmes periodically and optimize the metabolic index of control. In Hong Kong, General Practitioners with solo-practice (GP-SP) have the least availability of resources and support in DM management. A discrepancy of diabetes care between public and private settings and a gap of clinical practice between public-private healthcare settings is identified. In relation to the big population of T2DM is caring by GP-SP but no structured Diabetes Care Programme (DCP) is in place. A structured DCP for T2DM is in need to fill up the clinical gap and make beneficial to the target subjects.
The aim of this study is to evaluate the effectiveness of a DCP for people with T2DM in primary care settings. It is a multi-center, single-blind randomized controlled trial with parallel groups pre-test and post-test design. The evidence-based intervention (DCP) will be carried out in a private primary care setting. People with T2DM attending the GP-SP who meet the study criteria will be randomly assigned into one of the two study groups, either "DCP in addition to usual medical care" or "Usual medical care only" as a control group. The intervention group can beneficial in clinical and psychosocial outcomes after the completion of the 20-week structured DCP with a greater improvement of HbA1c level, Self-Efficacy in diabetes management, Diabetes Empowerment level, Diabetes Knowledge, and Quality of Life than those who only received usual medical care at the GP-SP.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This study is to implement an evidence-based develop Diabetes Care Programme (DCP) for 152 adults with Type 2 Diabetes Mellitus (T2DM) in a few clinics of a general practitioner with solo-practice (GP-SP) in community, and evaluate its effectiveness by comparing the outcomes between study group (DCP with the usual medical care) and control group (Usual medical care only). It is believed that a structured DCP can promote greater clinical outcomes improvement and behavioral changes in the study group as evidence showed in literature. The primary outcomes are glycemic control (HbA1c level) and Self-Efficacy in diabetes management; whereas Diabetes Empowerment level, Diabetes Knowledge and Quality of Life are the secondary outcomes.
The DCP consists of two parts, conduct 3 interactive group education with an innovative educational tool "Diabetes Conversation Map™" sessions by dietitian and diabetes educator/nurse. Then it followed by another 8 weeks for delivering two 15-30 minutes teleconsultations for patient empowerment and follow-up of "Action Plan" by a diabetes educator/nurse. Evaluation of outcomes will be done before the DCP (baseline), at week-8 (right after the group sessions), and at week-20 (4 weeks after the last teleconsultation).
In addition, a focus group interview will be carried out after the completion of the whole intervention. It purposes to explore and get valuable descriptive information and feelings from participants about the intervention and diabetes self-management.
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Hong Kong SAR
-
Hong Kong, Hong Kong SAR, Hongkong, Hong Kong
- Rekrutierung
- Clinics of private general practitioners
-
Kontakt:
- Kwok Wai A CHEUNG, Dr.
- Telefonnummer: +852-9844-4955
- E-Mail: alvinckw2000@yahoo.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- People with T2DM and follow up at private general practitioner
- Age 18-75
- Haemoglobin A1c (HbA1c) >7.0%
- Can communicate in Cantonese
Exclusion Criteria:
- Insulin users
- Unstable emotional and/or mental status
- Cognitive impairment and/or learning disabilities
- Recruited in other research and/or diabetes educational programme during the study period
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Diabetes Care Programme
People with Type 2 Diabetes Mellitus of private general practitioner (GP) with solo-practice who receive the intervention (Diabetes Care Programme) in addition to usual medical care at the GP
|
20-week Diabetes Care Programme consists of three Diabetes Conversation Map sessions in 8 weeks with 3-4 weeks intervals, then two teleconsultations at week 12th and week 16th
|
|
Kein Eingriff: Standard Usual Care
People with Type 2 Diabetes Mellitus of private general practitioner (GP) with solo-practice who only receive the usual medical care at the GP
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Glycated haemoglobin (HbA1c)
Zeitfenster: Change from Baseline HbA1c at week 20
|
Glycemic control
|
Change from Baseline HbA1c at week 20
|
|
Self-efficacy level in diabetes management
Zeitfenster: Change from Baseline Self-efficacy level at week 8
|
To assess the Self-efficacy level in diabetes management of Chinese people with diabetes.
Includes 20 items of self-care in six domains with 1-10 rating scale.
Higher score means better self-care.
|
Change from Baseline Self-efficacy level at week 8
|
|
Self-efficacy level in diabetes management
Zeitfenster: Change from Baseline Self-efficacy level at week 20
|
To assess the Self-efficacy level in diabetes management of Chinese people with diabetes.
Includes 20 items of self-care in six domains with 1-10 rating scale.
Higher score means better self-care.
|
Change from Baseline Self-efficacy level at week 20
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Diabetes Empowerment Scale
Zeitfenster: Change from Baseline Psycho-social Self-efficacy level at week 8
|
To assess the overall psycho-social self-efficacy level of Chinese people with diabetes.
It includes 10 items with a 1-5 rating scale.
A higher score means a higher level of self-efficacy.
|
Change from Baseline Psycho-social Self-efficacy level at week 8
|
|
Diabetes Empowerment Scale
Zeitfenster: Change from Baseline Psycho-social Self-efficacy level at week 20
|
To assess the overall psycho-social self-efficacy level of Chinese people with diabetes.
It includes 10 items with a 1-5 rating scale.
A higher score means a higher level of self-efficacy.
|
Change from Baseline Psycho-social Self-efficacy level at week 20
|
|
Diabetes Knowledge Questionnaire
Zeitfenster: Change from Baseline Diabetes self-care knowledge at week 8
|
To assess the Diabetes self-care knowledge of Chinese people with diabetes.
It includes 24 items of diabetes self-care knowledge with the total score range from 0-24.
Valid responses with "yes", "no" or "I don't know"; only scored on correct answers.
A higher score means a higher level of diabetes knowledge.
|
Change from Baseline Diabetes self-care knowledge at week 8
|
|
Diabetes Knowledge Questionnaire
Zeitfenster: Change from Baseline Diabetes self-care knowledge at week 20
|
To assess the Diabetes self-care knowledge of Chinese people with diabetes.
It includes 24 items of diabetes self-care knowledge with the total score range from 0-24.
Valid responses with "yes", "no" or "I don't know"; only scored on correct answers.
A higher score means a higher level of diabetes knowledge.
|
Change from Baseline Diabetes self-care knowledge at week 20
|
|
Quality of life Measurement
Zeitfenster: Change from Baseline Quality of Life status at week 8
|
The valuation of health status (quality of life) of Chinese people.
It includes 5 health dimensions with a sum of negative validity & 1 visual analog scale to reflect the self-rated health score.
A higher score means a higher quality of life status.
|
Change from Baseline Quality of Life status at week 8
|
|
Quality of life Measurement
Zeitfenster: Change from Baseline Quality of Life status at week 20
|
The valuation of health status (quality of life) of Chinese people.
It includes 5 health dimensions with a sum of negative validity & 1 visual analog scale to reflect the self-rated health score.
A higher score means a higher quality of life status.
|
Change from Baseline Quality of Life status at week 20
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Hau Yee H CHUNG, Chinese University of Hong Kong
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CREC2019.290
- Clinical Research Ethics (Andere Kennung: Joint CUHK-NTEC CREC)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Diabetes mellitus, Typ 2
-
Instituto Nacional de Ciencias Medicas y Nutricion...Aktiv, nicht rekrutierend
-
ENBIOSIS BIOTECHNOLOGIESAydin Adnan Menderes University; Izmir University of Economics; Buca Seyfi Demirsoy... und andere MitarbeiterNoch keine RekrutierungTyp 2 Diabetes | Diabetes mellitus Typ 2Türkei (türkiye)
-
Endogenex, Inc.Noch keine RekrutierungDiabetes mellitus, Typ 2 | Diabetes | Typ 2 Diabetes mellitus | Typ 2 Diabetes | Typ 2 Diabetes
-
Endogenex, Inc.Noch keine RekrutierungDiabetes mellitus, Typ 2 | Diabetes | Typ 2 Diabetes | Typ-2-Diabetes mellitus (T2DM) | Typ 2 Diabetes
-
SanofiAbgeschlossenDiabetes mellitus Typ 1 – Diabetes mellitus Typ 2Ungarn, Russische Föderation, Deutschland, Polen, Japan, Vereinigte Staaten, Finnland
-
University of North Carolina, Chapel HillAmerican Heart AssociationRekrutierungTyp 2 Diabetes | Ernährung | Diabetes Typ 2 | T2DM (Typ-2-Diabetes mellitus) | Diabetes mellitis | T2DM | Diabetes-AufklärungVereinigte Staaten
-
University of SalamancaUniversity of Salamanca; Instituto Piaget; Escola Superior de Tecnologia da Saúde...Anmeldung auf EinladungTyp 2 Diabetes mellitus | Altern | Hyperglykämie aufgrund von Diabetes mellitus Typ 2Portugal
-
Indonesia UniversityAbgeschlossen
-
US Department of Veterans AffairsAmerican Diabetes AssociationAbgeschlossenTyp 2 Diabetes mellitusVereinigte Staaten
-
University Hospital Inselspital, BerneAbgeschlossen
Klinische Studien zur Diabetes Care Programme
-
The Second Hospital of Shandong UniversityAktiv, nicht rekrutierend
-
Vegenat, S.A.UnbekanntHyperglykämie | Metabolisches Syndrom | DiabetikerSpanien
-
Xuanwu Hospital, BeijingBioray LaboratoriesNoch keine RekrutierungMultiple Sklerose | Neuromyelitis-Optica-Spektrum-Erkrankungen | Chronisch entzündliche demyelinisierende Polyradikuloneuropathie | Myasthenia gravis, verallgemeinertChina
-
Zhejiang UniversityCarbiogene Therapeutics Co. Ltd.RekrutierungFortgeschrittenes hepatozelluläres KarzinomChina
-
Nexcella Inc.Immix Biopharma, Inc.RekrutierungLeichtketten (AL)-AmyloidoseVereinigte Staaten
-
Second Affiliated Hospital, School of Medicine,...RekrutierungRezidiviertes und refraktäres B-Zell-LymphomChina
-
Second Affiliated Hospital, School of Medicine,...Rekrutierung
-
The Second Hospital of Shandong UniversityAktiv, nicht rekrutierendSicherheit und Wirksamkeit zellulärer Arzneimittel, objektive Ansprechrate der Probanden uswChina
-
Southwest Hospital, ChinaUnbekanntLymphom, große B-Zelle, diffusChina
-
Peking University Third HospitalRekrutierungRefraktärer systemischer Lupus erythematodesChina